Eteplirsen-treated boys with DMD who could perform the six-minute walk test showed continued stability in walking distance at week 120 of a phase 2b trial
Update (Jan. 16, 2014): Read Eteplirsen Data Still Strong: Treated Boys with DMD Stable at 120 Weeks for a recap of Sarepta's Jan. 15 presentation.
Boys with Duchenne muscular dystrophy (DMD) participating in a phase 2b extension trial of the experimental exon-skipping drug eteplirsen showed continued stabilization of walking distance at 120 weeks. Sarepta Therapeutics, developer of eteplirsen, announced the findings in a Jan. 15, 2014, press release.
A webcast of Sarepta’s presentation at the J.P Morgan Healthcare Conference will be available on the Sarepta site today at 4:30 p.m. Pacific (7:30 p.m. Eastern).